According to a new press release, Kanavos Inc. has announced a groundbreaking partnership with Graphwise and HomeLab to develop the cannabis industry’s first knowledge graph for patients seeking evidence-based cannabinoid therapies. This AI-powered system integrates scientific research, clinical trials, preclinical studies, and real-world data to provide personalized, actionable insights for healthcare providers and patients. The collaboration aims to address significant challenges in cannabinoid-based medicine, including fragmented data and the lack of personalized therapeutic recommendations.

By utilizing Graphwise’s advanced semantic AI technology, the knowledge graph will empower patients with a unified platform to discover and compare cannabinoid-based treatments, helping them make informed healthcare decisions. The system goes beyond generative AI, which focuses on content creation, by deeply analyzing relationships within data to deliver meaningful insights. Kanavos’ Chief Knowledge Officer, Dr. Deborah McGuinness, highlighted that this system simplifies the complex landscape of cannabinoid research for both patients and their care teams.

The Kanavos knowledge graph will serve as a crucial tool in bridging gaps in cannabis research, ensuring patients have access to the most relevant and up-to-date information. With this initiative, Kanavos, Graphwise, and HomeLab are poised to revolutionize the future of cannabinoid-based healthcare by providing a powerful resource for improving patient outcomes and advancing the field of cannabinoid therapeutics.